SuanFarma-Header SuanFarma-Header

X

Find Rheumatology Clinical Drug Pipeline Developments & Deals

Loading...

All Data

Filters Filter
×
FILTER:
filter Study Phase
    filter Country
      filter News Type
        filter Company
          filter Product Type

            Active Filter(s):

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Dotinurad

            Therapeutic Area: Rheumatology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 25, 2020

            Details:

            Under this agreement, Eisai will proceed with the development of dotinurad in China.